POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.

NCT07433192 · clinicaltrials.gov ↗
RECRUITING
Status
300
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Servier Russia